lytacs

Tri-GalNAc-COOH is a ligand for the asialoglycoprotein receptor (ASGPR) and is commonly used in lysosomal targeting chimera (LYTAC) investigations.

TriGalNAc CBz is a GalNAc derivative. As an ASGPR ligand, tri-GalNAc targets lysosomes in mRNA drug delivery and LYTAC studies.L-DABA hydrobromide.

Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl-modified triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand utilized in the synthesis of GalNAc-lysosome-targeting chimeras (LYTACs). These chimeras facilitate targeted protein degradation through engagement with the asialoglycoprotein receptor [1].

Tri-GalNAc-NHS ester is a high-affinity triantennary N-acetylgalactosamine (GalNAc) derivative acting as a specific ligand for the Asialoglycoprotein Receptor (ASGPR) with a Kd of approximately 2.5 nM, which conjugates to antibodies via the NHS ester moiety to construct Lysosome Targeting Chimeras (LYTACs) for the liver-specific degradation of extracellular proteins.

Tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) is a ligand for asialoglycoprotein receptors (ASGPR) applicable in lysosome-targeting chimera (LYTAC) research.

Allyl-mannose-6-phosphonate (M6Pn; Compound 6) is a stable analog of mannose-6-phosphate (M6P). It is utilized in the synthesis of M6Pn-peptide conjugates for the construction of lysosome-targeting chimeras (LYTAC).

GalNac-siRNA negative control (21nt) serves as the negative control form of GalNac-siRNA. GalNac-siRNA is an inhibitor conjugate targeting the asialoglycoprotein receptor (ASGPR). This compound holds potential for research into hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia, and hypercholesterolemia.

Tri-GalNAc biotin, a small molecule lysosome targeting degrader, serves as a ligand for the asialoglycoprotein receptor (ASGPR). It promotes the uptake of NeutrAvidin (NA) into liver cells via ASGPR and directs NeutrAvidin to the lysosome for degradation. This compound is applicable in the study of Lysosome Targeting Chimeras (LYTAC) [1].

Tri-GalNAc(OAc)3, a triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand, is utilized in the synthesis of GalNAc-lysosome targeting chimeras (LYTAC). These chimeras exploit the asialoglycoprotein receptor to direct protein degradation targets to the lysosome [1].

Tri-GalNAc(OAc)3 TFA, a triantenerrary N-acetylgalactosamine (tri-GalNAc) ligand, is utilized in the synthesis of GalNAc-lysosome-targeting chimera (GalNAc-LYTAC). This compound facilitates targeted protein degradation by engaging with the asialoglycoprotein receptor [1].

Tri-GalNAc-DBCO is a PIP-GalNAc coupling compound that binds ASGPR to drive protein down-regulation and target compounds for protein degradation via copper-free strain-promoted azide-alkyne cycloaddition coupled to azide on a non-specifically labeled antibody.

Tri-GalNAc-COOH acetylation represents the acetylated derivative of tri-galactosamine (tri-GalNAc-COOH), utilized in the synthesis of lysosome targeting chimeras (LYTAC).

M-MoDE-A (2) is a bifunctional small molecule that promotes the degradation of extracellular proteins through the asialoglycoprotein receptor (ASGPR).

D-MoDE-A (1) is a bifunctional small molecule that promotes extracellular protein degradation through the asialoglycoprotein receptor (ASGPR).

ASGPR ligand-1 is a compound that targets the asialoglycoprotein receptor (ASGPR) and is utilized in various disease research contexts [1].

dPDL1-4 is a potent and selective eHSPTAC eHSP90PD-L1 degrader, with DC50 values of 7.77 μM (HeLa) and 6.52 μM (B16F10). It links eHSP90 to target proteins, inducing lysosomal degradation. dPDL1-4 effectively degrades PD-L1 and inhibits tumor growth, making it useful for research in cervical cancer and melanoma.

HSP90i-COCH2CH2-PEG4-NHBoc is a conjugate consisting of an HSP90 ligand and a linker. This compound is useful in the synthesis of LYTACs, such as dPDL1-4.

HSP90i is a ligand of SHP90 and can be utilized in the synthesis of LYTACs, such as dPDL1-4.

Tri-GalNAc-PEG3-Azide is a specialized compound designed for lysosomal targeting chimera (LYTAC) research, featuring three asialoglycoprotein receptor (ASGPR) ligands linked by a PEG3 spacer and an azide group for easy conjugation. This compound facilitates efficient internalization into hepatocytes through ASGPR-mediated endocytosis, making it a strategic tool for delivering RNA, Cas9 complexes, or other cargo specifically to liver cells. Additionally, it can be utilized to create LYTACs or to be marked with a dye for tissue imaging applications.